Provided by Tiger Fintech (Singapore) Pte. Ltd.

CSPC PHARMA

8.030
+0.0801.01%
Volume:42.57M
Turnover:340.27M
Market Cap:92.52B
PE:19.89
High:8.070
Open:7.820
Low:7.820
Close:7.950
52wk High:11.454
52wk Low:4.152
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:1.13
T/O Rate:0.37%
Dividend:0.25
Dividend Rate:3.07%
EPS(LYR):0.404
ROE:10.83%
ROA:5.65%
PB:2.54
PE(LYR):19.89
PS:3.25

Loading ...

CSPC PHARMA (01093): SYH2061 Injection (Dual-Chain Small Interfering RNA Drug) Approved for Clinical Trials in China

Stock News
·
Oct 24

CSPC Pharmaceutical - Syh2061 Injection Obtains Clinical Trial Approval in China

THOMSON REUTERS
·
Oct 24

Hunan Jingfeng's Restructuring Begins: The Multiple Risks and Challenges Behind CSPC Pharma's Takeover

Deep News
·
Oct 24

CSPC Pharmaceutical Group Stock Slips 3.0% in Hong Kong, Underperforms Competitors

Dow Jones
·
Oct 23

Short Selling Statistics of Hong Kong Stocks | October 23

Stock News
·
Oct 23

CSPC Pharmaceutical Group Stock Slides 1.1% in Hong Kong, Underperforms Competitors

Dow Jones
·
Oct 21

How Breakthrough Therapy Status for JSKN003 at CSPC Pharmaceutical Group (SEHK:1093) Has Changed Its Investment Story

Simply Wall St.
·
Oct 21

BRIEF-CSPC Pharmaceutical Says JSKN003 Granted Breakthrough Therapy Designation In China

Reuters
·
Oct 20

CSPC PHARMA (01093): JSKN 003 Receives Breakthrough Therapy Designation in China for Treatment of HER2-positive Advanced Colorectal Cancer

Stock News
·
Oct 20

CSPC (1093) Gains Second Breakthrough Therapy Designation for JSKN003 in Advanced Colorectal Cancer

Bulletin Express
·
Oct 20

Equity Disclosure of CSPC PHARMA | October 20

Stock News
·
Oct 20

Alphamab Oncology and Shanghai JMT-Bio Secure Breakthrough Therapy Designation for JSKN003 in HER2+ Advanced Colorectal Cancer

Reuters
·
Oct 20

CSPC Pharmaceutical - Jskn003 Granted Breakthrough Therapy Designation in China

THOMSON REUTERS
·
Oct 20

CSPC PHARMA Chairman Cai Dongchen Acquires 3 Million Shares at HKD 8.81 Each

Deep News
·
Oct 20

Alphamab Oncology Announces Positive Phase III Trial Results for KN026 in HER2+ Gastric Cancer at ESMO Congress 2025

Reuters
·
Oct 17

Chairman and Executive Director Cai Dongchen Increases Stake in CSPC PHARMA (01093) by 3 Million Shares at HK$8.81 Each

Stock News
·
Oct 17

CSPC Pharmaceutical (1093) Announces On-Market Purchase of 3,000,000 Shares

Bulletin Express
·
Oct 17

CSPC PHARMA (01093): Trustee Acquires a Total of 3 Million Shares Under the Share Award Plan

Stock News
·
Oct 17

CSPC Pharmaceutical Group Ltd. Buys Back 3,000,000 Shares at Average Price of HK$8.86 Each for Approximately HK$26.59 Million

Reuters
·
Oct 17

CSPC Pharmaceutical Group Stock Sheds 4.1% in Hong Kong

Dow Jones
·
Oct 17